Neurocrine Biosciences IncNBIX
Price$140.71Intrinsic value$383.60173% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $383.60median of 6 methods · middle span $227-$2,819based on filings through 30 Jun 2026
Market Price $140.71Price as of 1 Oct 2026
Margin of Safety +172.6%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 25.1% (near-term consensus, capped) · years 2–5: 42.5%/yr (balance of the path).38.9% per year
Years 6–10: glide to demonstrated growth own history 51.3%, capped at 20%
Per-year rates
Yr 638.0%Yr 733.5%Yr 829.0%Yr 924.5%Yr 1020.0%
42.5% → 20.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1118.3%Yr 1216.6%Yr 1314.9%Yr 1413.2%Yr 1511.5%Yr 169.8%Yr 178.1%Yr 186.4%Yr 194.7%Yr 203.0%
20.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)51.3%
Discount rate (cost of equity) 7.6%
Volatility vs market (adjusted beta)0.60

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetNeurocrine Biosciences IncNBIXHealth Care
Valuation
P/E20.6×
P/S4.6×
P/B4.3×
EV / Revenue4.5×
EV / EBITDA—
Profitability
Gross margin—
Operating margin23.6%
Net margin20.9%
FCF margin25.8%
Returns
ROE19.1%
ROA13.2%
ROIC21.0%
Growth
Revenue growth (YoY)43.2%
5-yr fwd EPS growth38.9%
Financial strength
Debt / Equity0.00×
Current ratio1.87×
Altman Z-Score6.7
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.